Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.

导出 LinkOut

翻译打印收藏纠错

作者： Zhansheng,Jiang ^[1] ; Jing,Zhang ^[2] ; Haiyan,Sun ^[3] ; Cong,Wang ^[1] ; Yu,Zhang ^[2] ; Yanyang,Li ^[3] ; Zhanyu,Pan ^[1]

作者单位： Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. ^[1] Key Laboratory for Cancer Prevention and Therapy, Tianjin, China. ^[2] Tianjin's Clinical Research Center for Cancer, Tianjin, China. ^[3]

关键词 bevacizumab combination therapy epidermal growth factor receptor (EGFR)icotinib non-small cell lung cancer (NSCLC)

主题词成年人(Adult);老年人(Aged);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);中国(China);冠醚类(Crown Ethers);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);喹唑啉类(Quinazolines);回顾性研究(Retrospective Studies)

DOI 10.1111/1759-7714.14079

PMID 34255422

发布时间 2022-01-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Thoracic cancer

2021年12卷17期

2369-2374页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.

Thoracic cancer

相似文献

Thoracic cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.

Thoracic cancer

相似文献

Thoracic cancer

相关期刊

检索历史清除